Indaptus Therapeutics (INDP) Competitors $7.81 -0.63 (-7.46%) Closing price 03:59 PM EasternExtended Trading$7.74 -0.06 (-0.83%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. SYBX, LSB, HOTH, IMNN, MTEX, LEXX, LPCN, CLDI, BLRX, and NRSNShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Synlogic (SYBX), LakeShore Biopharma (LSB), Hoth Therapeutics (HOTH), Imunon (IMNN), Mannatech (MTEX), Lexaria Bioscience (LEXX), Lipocine (LPCN), Calidi Biotherapeutics (CLDI), BioLineRx (BLRX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Synlogic LakeShore Biopharma Hoth Therapeutics Imunon Mannatech Lexaria Bioscience Lipocine Calidi Biotherapeutics BioLineRx NeuroSense Therapeutics Indaptus Therapeutics (NASDAQ:INDP) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Which has higher valuation and earnings, INDP or SYBX? Indaptus Therapeutics has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$41.74-0.19Synlogic$10K1,696.50-$23.36M-$2.51-0.58 Which has more risk and volatility, INDP or SYBX? Indaptus Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Do insiders and institutionals have more ownership in INDP or SYBX? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 20.8% of Indaptus Therapeutics shares are held by insiders. Comparatively, 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor INDP or SYBX? In the previous week, Indaptus Therapeutics had 4 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Indaptus Therapeutics and 2 mentions for Synlogic. Synlogic's average media sentiment score of 0.29 beat Indaptus Therapeutics' score of -0.17 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment Indaptus Therapeutics Neutral Synlogic Neutral Is INDP or SYBX more profitable? Synlogic's return on equity of -8.09% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -399.14% -242.40% Synlogic N/A -8.09%-5.50% Do analysts rate INDP or SYBX? Indaptus Therapeutics presently has a consensus target price of $238.00, suggesting a potential upside of 2,947.38%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Indaptus Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIndaptus Therapeutics beats Synlogic on 8 of the 14 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.83M$2.48B$5.62B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.2122.0530.2925.74Price / SalesN/A742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book0.724.838.826.15Net Income-$15.02M$31.61M$3.25B$265.06M7 Day Performance15.88%3.93%4.05%2.80%1 Month Performance-37.92%3.32%4.32%1.68%1 Year Performance-83.40%13.53%36.25%29.59% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics3.2392 of 5 stars$7.81-7.5%$238.00+2,947.4%-82.2%$4.83MN/A-0.216News CoverageGap DownSYBXSynlogic0.956 of 5 stars$1.46+5.8%N/A+9.5%$17.08M$10K-0.5880Short Interest ↑Gap UpHigh Trading VolumeLSBLakeShore Biopharma1.4739 of 5 stars$0.81+0.9%N/A-81.3%$16.82M$85.67M0.00773Positive NewsUpcoming EarningsShort Interest ↓Gap DownHOTHHoth Therapeutics3.2494 of 5 stars$1.27+9.5%$4.00+215.0%+114.4%$16.78MN/A-1.114Earnings ReportShort Interest ↓IMNNImunon1.868 of 5 stars$6.84-3.4%$232.50+3,299.1%-58.6%$16.69M$500K-0.5330Short Interest ↑MTEXMannatech0.4542 of 5 stars$8.71+8.9%N/A+38.7%$16.55M$117.87M-87.10250News CoverageEarnings ReportShort Interest ↑Gap DownTrading HaltedLEXXLexaria Bioscience3.7902 of 5 stars$0.83+1.5%$4.00+379.9%-74.3%$16.30M$460K-1.247News CoverageShort Interest ↓LPCNLipocine2.8937 of 5 stars$2.97+0.7%$9.00+203.0%-20.8%$16.10M$11.20M-3.4110News CoveragePositive NewsAnalyst UpgradeCLDICalidi Biotherapeutics0.7747 of 5 stars$5.29+5.0%N/A-70.4%$16.01MN/A0.0038Short Interest ↓BLRXBioLineRx3.1422 of 5 stars$3.75+0.8%$26.00+593.3%-87.3%$15.98M$28.94M-0.4340News CoverageEarnings ReportGap DownNRSNNeuroSense Therapeutics2.3864 of 5 stars$1.12-6.7%$14.00+1,150.0%+78.6%$15.31MN/A-2.0710Short Interest ↑High Trading Volume Related Companies and Tools Related Companies SYBX Alternatives LSB Alternatives HOTH Alternatives IMNN Alternatives MTEX Alternatives LEXX Alternatives LPCN Alternatives CLDI Alternatives BLRX Alternatives NRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access